Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Capital Expenditures (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Capital Expenditures for 16 consecutive years, with -$11.5 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 13.31% to -$11.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 98.49% year-over-year, with the annual reading at $1.0 million for FY2025, 98.49% up from the prior year.
  • Capital Expenditures hit -$11.5 million in Q4 2025 for Ani Pharmaceuticals, down from $6.1 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $12.2 million in Q3 2024 to a low of -$13.3 million in Q4 2024.
  • Historically, Capital Expenditures has averaged $245800.0 across 5 years, with a median of $612000.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: soared 3258.06% in 2021 and later plummeted 2624.6% in 2023.
  • Year by year, Capital Expenditures stood at $356000.0 in 2021, then tumbled by 30.34% to $248000.0 in 2022, then tumbled by 2624.6% to -$6.3 million in 2023, then crashed by 112.63% to -$13.3 million in 2024, then rose by 13.31% to -$11.5 million in 2025.
  • Business Quant data shows Capital Expenditures for ANIP at -$11.5 million in Q4 2025, $6.1 million in Q3 2025, and $4.0 million in Q2 2025.